[HTML][HTML] Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast …
DJ Slamon, P Neven, S Chia, G Jerusalem… - Annals of oncology, 2021 - Elsevier
Background Ribociclib plus fulvestrant demonstrated significant progression-free survival
(PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human …
(PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human …
[HTML][HTML] 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
F Cardoso, S Paluch-Shimon, E Schumacher-Wulf… - The breast, 2024 - Elsevier
This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
Phase I or II study of ribociclib in combination with topotecan-temozolomide or everolimus in children with advanced malignancies: arms A and B of the AcSé-ESMART …
F Bautista, X Paoletti, J Rubino, C Brard… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE AcSé-ESMART is a proof-of-concept, phase I or II, platform trial, designed to
explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to …
explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to …
Clinical implications of the Drug-Drug interaction in cancer patients treated with innovative oncological treatments
F Santamaria, M Roberto, D Buccilli… - Critical Reviews in …, 2024 - Elsevier
In the last two-decades, innovative drugs have revolutionized cancer treatments,
demonstrating a significant improvement in overall survival. These drugs may present …
demonstrating a significant improvement in overall survival. These drugs may present …
A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs
L Boscolo Bielo, S Natangelo, J Katrini… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Drugs available for the treatment of breast cancer are increasing, yielding
improved oncological outcomes. The efficacy and safety of anticancer drugs significantly …
improved oncological outcomes. The efficacy and safety of anticancer drugs significantly …
An integrated pharmacological counselling approach to guide decision-making in the treatment with CDK4/6 inhibitors for metastatic breast cancer
R Roncato, L Gerratana, L Palmero, S Gagno… - Frontiers in …, 2022 - frontiersin.org
A wide inter-individual variability in the therapeutic response to cyclin-dependent kinases 4
and 6 inhibitors (CDKis) has been reported. We herein present a case series of five patients …
and 6 inhibitors (CDKis) has been reported. We herein present a case series of five patients …
Ribociclib cytotoxicity alone or combined with progesterone and/or mitotane in in vitro adrenocortical carcinoma cells
A Abate, E Rossini, M Tamburello, M Laganà… - …, 2022 - academic.oup.com
Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC). The
regimen added to mitotane is chemotherapy with etoposide, doxorubicin, and cisplatin. This …
regimen added to mitotane is chemotherapy with etoposide, doxorubicin, and cisplatin. This …
Ribociclib population pharmacokinetics and pharmacokinetic/pharmacodynamic analysis of neutrophils in cancer patients
Y Lu, S Yang, YY Ho, Y Ji - The Journal of Clinical …, 2021 - Wiley Online Library
The population pharmacokinetics (popPK) of ribociclib and population pharmacokinetic/
pharmacodynamic (PK/PD) relationship between ribociclib and absolute neutrophil count …
pharmacodynamic (PK/PD) relationship between ribociclib and absolute neutrophil count …
Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time
D Malnoë, O Fardel, P Le Corre - Pharmaceutics, 2022 - mdpi.com
(1) Background: Oral targeted anticancer drugs are victims of presystemic pharmacokinetic
drug–drug interactions (DDI). Identification of the nature of these DDIs, ie, enzyme-based …
drug–drug interactions (DDI). Identification of the nature of these DDIs, ie, enzyme-based …
Justifying ribociclib dose in patients with advanced breast cancer with renal impairment based on PK, safety, and efficacy data: An innovative approach integrating …
Y Ji, V Yartsev, M Quinlan, P Serra, Y Wang… - Clinical …, 2023 - Springer
Abstract Background and Objective Renal impairment is common in patients with cancer
and can alter the PK and thus the safety and efficacy of drugs. We assessed the impact of …
and can alter the PK and thus the safety and efficacy of drugs. We assessed the impact of …